08:00 , Jan 2, 2012 |  BC Week In Review  |  Clinical News

Galaczym regulatory update

FDA granted Orphan Drug designation for Galaczym from Zymenex's Ace Biosciences A/S subsidiary to treat globoid cell leukodystrophy (Krabbe disease), a hereditary disease caused by a deficiency of galactocerebrosidase. The recombinant human enzyme is in...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

Galaczym regulatory update

The European Commission granted Orphan Drug designation for Galaczym from Zymenex's Ace Biosciences A/S subsidiary to treat globoid cell leukodystrophy (Krabbe disease), a hereditary disease caused by a deficiency of galactocerebrosidase. The recombinant human enzyme...
08:00 , Dec 13, 2010 |  BC Week In Review  |  Clinical News

ACE527: Phase II data

A double-blind, U.S. Phase II trial in 56 healthy volunteers showed that a 2-dose vaccination regimen with oral ACE527 missed the primary endpoint of significantly reducing the severity of diarrhea at 120 hours post-challenge with...
07:00 , Mar 29, 2010 |  BC Week In Review  |  Company News

Action Pharma metabolic, endocrine news

Action Pharma said its board will focus on partnering the company's lead programs and plans to explore M&A opportunities or consolidation. As part of this process, the company hired Ingelise Saunders as CEO. Saunders, formerly...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Clinical News

ACE527: Phase I data

In a double-blind, placebo-controlled, U.S. Phase I trial in 36 healthy volunteers, ACE527 was well tolerated and induced a mucosal immune response to colonization factors on all 3 strains of E. coli included in the...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Clinical News

ACE393: Phase IIb started

Ace BioSciences began a Phase IIb trial to compare 2 injections of ACE393 given 3 weeks apart vs. placebo in 60 healthy volunteers. Ace BioSciences A/S, Odense, Denmark   Product: ACE393   Business: Gastrointestinal   Molecular target:...
07:00 , Aug 25, 2008 |  BC Week In Review  |  Company News

Ace BioSciences board of directors update

Ace BioSciences A/S, Odense, Denmark   Business: Infectious   Appointed: David Colpman, SVP of business development at Shire plc   ...
07:00 , Jun 23, 2008 |  BC Week In Review  |  Company News

Ace BioSciences, Program for Appropriate Technology in Health infectious news

Ace will receive $5 million over two years from the not-for-profit PATH to develop Ace’s ACE527 (formerly ACE537) vaccine to prevent diarrhea caused by enterotoxigenic Escherichia coli (ETEC). PATH will receive an exclusive...
07:00 , May 26, 2008 |  BC Week In Review  |  Company News

Ace BioSciences management update

Ace Biosciences A/S, Odense, Denmark   Business: Infectious   Hired: Peter Birk as CSO, formerly VP of R&D for molecular biology and expression and R&D for immunology at Pharmexa A/S   ...
07:00 , Mar 17, 2008 |  BC Week In Review  |  Company News

Ace BioSciences, Program for Appropriate Technology in Health deal

Ace and the not for profit partnered to develop temperature-stable formulation technologies for use in vaccines to treat diarrhea. The research will be funded by PATH. Both parties will have access to the resulting technologies....